Finance

Lists
Q3 2026 earnings • released • EPS beat +51.77% • Revenue beat +0.70%
See results
ASND:NASDAQ
Ascendis Pharma A/S
$275.39
+3.12%
(+8.32) 1D
$275.39
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ASND...
Open
$267.40
High
$278.56
Low
$265.62
Mkt. cap
18.29B
Avg. vol.
720.87K
Volume
826.10K
P/E ratio
19.00
52-wk high
$282.15
52-wk low
$188.08
EPS
$14.50
Shares outstanding
62.38M
No. of employees
1K
Open
$267.40
High
$278.56
Low
$265.62
Mkt. cap
18.29B
Avg. vol.
720.87K
Volume
826.10K
P/E ratio
19.00
52-wk high
$282.15
52-wk low
$188.08
EPS
$14.50
Shares outstanding
62.38M
No. of employees
1K
News stories
From web sources and news partners
About Ascendis Pharma A/S
CEO-
Employees1.19K
Founded2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteascendispharma.com
Analyst ratings
Based on 20 analysts giving stock ratings to ASND in the past 3 months
Strong buy
Buy
19
Hold
1
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for ASND in the last 3 months.
Highest
Current $275.39
$356.00 (+29.27%)
Average
$319.11 (+15.88%)
Lowest
$274.00 (-0.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Buy
Maintained
$290.00
+5.3%
11/12/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$326.00
+18.4%
11/13/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$304.00
+10.4%
11/12/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$302.00
+9.7%
11/13/2026
Yun Zhong
Wedbush
Buy
Reiterated
$346.00
+25.6%
11/13/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$356.00
+29.3%
11/13/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$330.00
+19.8%
11/13/2026
Joon Lee
UBS
Buy
Reiterated
$315.00
+14.4%
11/13/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
$274.00
-0.5%
11/13/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$335.00
+21.6%
11/13/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$352.00
+27.8%
11/13/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$273.00
-0.9%
11/02/2026
Eric Joseph
Citi
Buy
Maintained
$330.00
+19.8%
10/26/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
-
-
10/10/2026
Eliana Merle
Barclays
Buy
Maintained
$329.00
+19.5%
09/30/2026
Li Watsek
Cantor Fitzgerald
Buy
Maintained
$300.00
+8.9%
09/25/2026
David Lebowitz
BMO Capital
Buy
Maintained
$319.00
+15.8%
09/14/2026
Martin Auster
Raymond James
Buy
Maintained
$287.00
+4.2%
09/15/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$312.00
+13.3%
09/02/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$326.00
+18.4%
09/01/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$312.00
+13.3%
09/02/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$330.00
+19.8%
08/31/2026
Evan Seigerman
BMO Capital
Buy
Initiated
$319.00
+15.8%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$319.00
+15.8%
08/18/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$300.00
+8.9%
07/27/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$295.00
+7.1%
05/20/2026
Unknown Analyst
Citi
Buy
Initiated
$355.00
+28.9%
05/15/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$324.00
+17.7%
04/13/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
€1.71 / €1.13
+51.77%beat
Revenue / Est. (EUR)
369.66M / 367.09M
+0.70%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
213.63M
247.50M
246.60M
339.28M
Cost of goods sold
22.35M
23.60M
17.52M
27.66M
Cost of revenue
22.35M
23.60M
17.52M
27.66M
Research and development expenses
66.88M
82.20M
59.04M
75.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
113.40M
139.31M
145.23M
173.34M
Operating expense
180.28M
221.51M
204.27M
91.16M
Total operating expenses
202.64M
245.11M
221.79M
118.82M
Operating income
11.00M
2.39M
24.81M
220.46M
Other non operating income
-
-105.57M
-
-
EBT including unusual items
-57.37M
-26.70M
-48.18M
230.09M
EBT excluding unusual items
-57.37M
-34.21M
-48.18M
230.09M
Income tax expense
3.62M
6.86M
-677.52M
23.12M
Effective tax rate
-6.30%
-25.68%
1,406.31%
10.05%
Other operating expenses
-
-
-
-158.07M
Net income
-60.99M
-33.56M
629.34M
206.97M
Net profit margin
-28.55%
-13.56%
255.21%
61.00%
Earnings per share
-1.00
-0.55
0.27
0.90
Interest and investment income
6.04M
64.06M
4.52M
19.96M
Interest expense
-66.90M
-74.65M
-67.26M
-14.17M
Net interest expenses
-60.87M
-10.59M
-62.74M
5.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
15.02M
3.60M
29.03M
225.03M
Gain or loss from assets sale
-
-
-
21.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps